Tibolone and osteoporosis

被引：7

作者：

Lazovic G. ^{[1
]}

Radivojevic U. ^{[2
]}

Milosevic V. ^{[3
]}

Lazovic A. ^{[4
]}

Jeremic K. ^{[1
]}

Glisic A. ^{[1
]}

机构：

[1] Institute of Gynecology and Obstetrics, Clinical Centre of Serbia, 11000 Belgrade

[2] Clinic for Human Reproduction, Mother and Child Health Care Institute of Serbia, Belgrade

[3] Institute for Biological Research, Sinisa Stankovic, Belgrade

[4] Special Orthopedic Hospital Banjica, Belgrade

来源：

Archives of Gynecology and Obstetrics | 2007年 / 276卷 / 6期

关键词：

Osteopenia; Osteoporosis; Postmenopausal women; Tibolone;

D O I：

10.1007/s00404-007-0387-4

中图分类号：

学科分类号：

摘要：

Background: We conducted a 5-year prospective, observational, controlled study to assess the effects of tibolone 1.25 mg/day on bone mineral density (BMD) in postmenopausal women with osteopenia or osteoporosis. Methods: The subjects were 420 women, an average of 66.4 years old, who had been postmenopausal between 8 and 19 years when enrolled in the study. Of the 420 women enrolled, 346 agreed to take tibolone for 5 years. The 74 who refused tibolone took only calcium/vitamin D supplements and served as the control group. BMD was measured in the lumbar spine and total hip region at baseline and annually by dual-energy X-ray absorptiometry (DXA). Results: At the first two follow-up visits, women taking tibolone had a significant increase in BMD at the spine (P < 0.001) and at the hip (P < 0.001) when compared to baseline values and when compared to BMD values for the control group, which decreased from baseline. In the final 3 years of the study, BMD values (spine and hip) continued to decrease in the control group and also tended to decrease in the tibolone group, but at the end of the fifth year, mean BMD in the tibolone group was still higher than BMD before the start of tibolone treatment (P < 0.05). Calculations showed that if women taking tibolone continued to lose BMD at the same rate as during the final 3 years of the study, after 11 years of tibolone treatment the average patient would have the same BMD as she had when treatment started. Conclusion: This 5-year observational study provides evidence that tibolone is effective in increasing BMD in postmenopausal women with osteopenia and osteoporosis during the first 2 years of treatment, but because BMD starts to decline in the third year, it is vital that postmenopausal women start treatment with tibolone as early as possible, so that bone mineral density levels are kept high as long as possible. © 2007 Springer-Verlag.

引用

页码：577 / 581

页数：4

共 21 条

[11]

Tang B.L.K., Markiewicz H.J., Gurpide E., Human endometrial 3ß-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14), J Steroid Biochem Mol Biol, 45, pp. 345-351, (1993)

[12]

Markiewicz L., Gurpide E., Estrogenic and progestagenic activities coexisting in steroidal drugs: Quantitative evaluation by in vitro bioassays with human cells, J Steroid Biochem Mol Biol, 48, pp. 89-94, (1994)

[13]

Geusens P., Dequeker J., Gielen J., Schot L.P.C., Non-linear increase in vertebral density induced by a synthetic steroid (ORG OD14) in women with established osteoporosis, Maturitas, 13, pp. 155-162, (1991)

[14]

Berning B., Kuijk C.V., Kuiper J.W., Coelingh Bennink H.J.T., Kicovic P.M., Bcjm F., Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized, placebo-controlled study, Bone, 19, pp. 395-399, (1996)

[15]

Bjarnason N.H., Bjarnason K., Jaarbo J., Rosenquist C., Christiansen C., Tibolone: Prevention of bone loss in late post-menopausal women, J Clin Endocrinol Metab, 81, pp. 2419-2422, (1996)

[16]

Lippuner K., Haenggi W., Birkhaeuser M.H., Casez J.P., Jaeger P., Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17ß-estradiol and dydrogesterone, J Bone Miner Res, 12, pp. 806-812, (1997)

[17]

Prelevic G.M., Bartram C., Wood J., Okolo S., Ginsburg J., Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women, Gynecol Endocrinol, 10, pp. 413-420, (1996)

[18]

Riggs B.L., Editorial: Tibolone as an alternative to estrogen for the prevention of postmenopausal osteoporosis in selected postmenopausal women, J Clin Endocrinol Metab, 81, pp. 2417-2418, (1996)

[19]

Gallagher J.C., Baylink J.D., Freeman R., McClung M., Prevention of bone loss with tibolone in postmenopausal women: Results of two randomized, double-blind, placebo-controlled, dose-finding studies, J Clin Endocrinol Metab, 86, pp. 4717-4726, (2001)

[20]

Yu B., Tanko L., Alexandersen P., Et al., Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study, Bone, 34, pp. 728-735, (2004)

← 1 2 3 →